| dc.contributor.author | González Iglesias, Verónica | |
| dc.contributor.author | Salgueiro Vázquez, Esther | |
| dc.contributor.author | Jimeno Demuth, Francisco José | |
| dc.contributor.author | Hidalgo Balsera, Agustín | |
| dc.contributor.author | Rubio Alfonso, Tania | |
| dc.contributor.author | Manso Rodríguez, Gloria | |
| dc.date.accessioned | 2013-01-30T09:55:36Z | |
| dc.date.available | 2013-01-30T09:55:36Z | |
| dc.date.issued | 2008 | |
| dc.identifier.citation | Pharmacoepidemiology and Drug Safety, 17(7), p. 714-721 (2008); doi:10.1002/pds.1587 | spa |
| dc.identifier.issn | 1053-8569 | |
| dc.identifier.uri | http://hdl.handle.net/10651/5780 | |
| dc.format.extent | p. 714-721 | spa |
| dc.language.iso | eng | |
| dc.relation.ispartof | Pharmacoepidemiology and Drug Safety | spa |
| dc.rights | (c) Pharmacoepidemiology and Drug Safety | |
| dc.source | WOK | spa |
| dc.title | Post-marketing safety of antineoplasic monoclonal antibodies: rituximab and trastuzumab | spa |
| dc.type | journal article | |
| dc.identifier.local | 965 | spa |
| dc.identifier.doi | 10.1002/pds.1587 | |
| dc.relation.publisherversion | http://dx.doi.org/10.1002/pds.1587 | spa |
